By J. Andrew Case, Genentech/Roche and Daniel Getts, Myeloid Therapeutics
Published in: cell and gene / Thermo Fisher Scientific Bioproduction
Published on: December 5, 2023
mRNA-based treatments have already shown great promise as a potent therapeutic agent for cancer immunotherapy. As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS. Cell & Gene Chief Editor Erin Harris hosted expert panelists J. Andrew Case, Head of Supply Chain Cell and Gene Therapies at Genentech/Roche and Daniel Getts, CEO & Co-Founder of Myeloid Therapeutics for a breakdown of ways to address uncoordinated and inefficient processes to promote greater stability and immunogenicity.
